Search Results
-
Post
Novocure Reports Third Quarter 2017 Financial Results and Provides Company Update
...60 days. (2) A “prescription received” is a commercial order for Optune that is received from a physician certified to treat patients with Optune for a patient not previously on...
-
Post
Novocure Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Company Update
...improvement in survival for patients treated with Optune together with temozolomide compared to patients treated with temozolomide alone,” continued Mr. Danziger. “Optune plus temozolomide is the first treatment in more...
-
Post
Novocure Reports Second Quarter 2017 Financial Results and Provides Company Update
...104.2 $ 120.0 (1) A “prescription received” is a commercial order for Optune that is received from a physician certified to treat patients with Optune for a patient not previously...
-
Post
Novocure Reports First Quarter 2017 Financial Results and Provides Company Update
...the end of period $ 104.7 $ 119.8 (1) A “prescription received” is a commercial order for Optune that is received from a physician certified to treat patients with Optune...
-
Post
Novocure Reports Third Quarter 2016 Financial Results and Provides Company Update
...October 2015 U.S. Food and Drug Administration (FDA) approval of Optune for the treatment of newly diagnosed glioblastoma (GBM), increased commercial activities in Germany, and enhanced awareness of Optune following...
-
Post
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
...clinical trial evaluating the safety and efficacy of initiating Optune Gio® (formerly known as Optune®) concurrent with radiation therapy and temozolomide (TMZ) for the treatment of adult patients with newly...
-
Post
First Patient Enrolled in Novocure’s EF-33 Phase 2 Pilot Trial of Tumor Treating Fields Delivered Utilizing High-Intensity Transducer Arrays
...which point Novocure will determine the appropriate regulatory pathway for potential commercial use. About Optune Optune is a noninvasive, antimitotic cancer treatment for GBM. Optune delivers Tumor Treating Fields to...
-
Post
Novocure Announces 38 Presentations on Tumor Treating Fields at 21st Annual Scientific Meeting of the Society of Neuro-Oncology
...treated with Optune® together with temozolomide will also be presented November 07, 2016 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that 38 abstracts focusing on...
-
Post
Novocure Honors Mesothelioma Day with Activities to Raise Awareness of Mesothelioma and Support the Community
...approval of Optune Lua, pemetrexed plus cisplatin was the only FDA-approved therapy for patients with MPM that could not be surgically removed. About Optune Lua Optune Lua is a noninvasive,...
-
Post
Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology
...not use Optune in patients with GBM with an implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with...